LongQTNext™
Use
The LongQTNext test is a comprehensive genetic analysis aimed at identifying inherited arrhythmias such as Long QT syndrome, Brugada syndrome, and short QT syndrome. These conditions are often asymptomatic but can lead to sudden cardiac death if undetected. Through analyzing a panel of 17 genes commonly associated with these syndromes, this test provides valuable confirmation necessary for directing medical management and treatment strategies. It is particularly useful for confirming diagnosis, clarifying cardiovascular disease risks, and fine-tuning management recommendations based on an individual’s genotype.
Special Instructions
Family variant testing is available at no additional cost for blood relatives of patients with identified pathogenic variants, provided testing is completed within 90 days of the original report date. Ambry Genetics exclusively offers this service to patients receiving care in the U.S. or U.S. territories.
Limitations
The LongQTNext panel is designed to detect over 99% of known mutations within the included genes. However, the clinical sensitivity might vary based on the patient's specific clinical history and family background. There may be challenges in detecting certain variants due to pseudogene interference, depth of coverage, or the technical constraints of Sanger sequencing for regions with insufficient read depth. Gross deletions/duplications are evaluated with custom pipelines and confirmatory orthogonal methods, noting that exon-level resolutions may sometimes not be achieved for all genes.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided